Paulo Ricardo Santos Nunes Filho

Dr. Paulo Ricardo Santos Nunes Filho

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Oncology and Therapy
Verified
Journal Article
Open access
PDF file
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
CACaroline Albuquerque
Caroline Albuquerque
MCMariana Pilon Capella
Mariana Pilon Capella
MDMarcio Debiasi
Marcio Debiasi
Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer’s prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). However, these medications are associated with unique side effects known as immune-mediated adverse events (irAE). In this paper, we review the clinical evidence for the use of ICIs in breast cancer, in both the metastatic as well as neoadjuvant/adjuvant setting, followed by a review of irAE most commonly seen, and the medications used to treat them. Our opinion is that any cancer specialist treating patients with breast cancer should be aware of these side effects for early detection and management, and oncologists should be the leaders of the multidisciplinary team that will take care of them.

12 March 2020 in Jornal de Pediatria
Verified
Journal Article
Open access
CJCíntia Junges
Cíntia Junges
TMTania Macahdo
Tania Macahdo
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
RRRudimar Riesgo
Rudimar Riesgo
EMElza Daniel de Mello
Elza Daniel de Mello
To measure the prevalence of vitamin D deficiency (through the 25-hydroxyvitamin D metabolite) in pediatric patients using antiepileptic drugs. Meta-analysis of studies identified through search in the PubMed, Embase, LILACS, and Cochrane Library databases, on February 19, 2019. A total of 748 articles were identified, 29 of which were relevant to the objectives of this study. The prevalence of vitamin D deficiency found was 0.32 (95% CI=0.25-0.41; I2=92%, p<0.01). In the subgroup analyses, the most significant results were observed in the group of patients using cytochrome P450-inducing antiepileptic drugs, with a prevalence of 0.33 (95% CI=0.21-0.47; I2=86%, p<0.01) and, considering the study design, in the subgroup of cohort studies, with a prevalence of 0.52 (95% CI=0.40-0.64; I2=76%, p<0.01). Taking into account the deleterious effects of vitamin D deficiency on the bone health of individuals using antiepileptic drugs, it is suggested to include in their care 25-hydroxyvitamin D monitoring, cholecalciferol supplementation, and treatment of the deficiency, when present.

27 October 2025 in Onco
Verified
Journal Article
Open access
PDF file
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
LCLarissa Ariel Oliveira Carrilho
Larissa Ariel Oliveira Carrilho
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
LCLuca Cantini
Luca Cantini
LVLaura Vidal
Laura Vidal
KSKamal S. Saini
Kamal S. Saini
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.

21 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
LCLarissa Ariel Oliveira Carrilho
Larissa Ariel Oliveira Carrilho
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
LCLuca Cantini
Luca Cantini
LVLaura Vidal
Laura Vidal
KSKamal S. Saini
Kamal S. Saini
The inflammatory milieu surrounding tumors plays a pivotal yet paradoxical role in promoting carcinogenesis. Rather than simply acting as a host defense mechanism, chronic low-grade inflammation actively nurtures tumor development and supports hallmarks such as sustained proliferative signaling, apoptosis resistance, angiogenesis, and metastasis. Obesity, characterized by a chronic inflammatory state, exacerbates this tumor-promoting environment through metabolic imbalances like insulin resistance, hyperglycemia, and dyslipidemia. These conditions stimulate oncogenic signaling pathways and reshape the tumor microenvironment. Obesity-associated cytokines, altered adipokines, and insulin-related growth signals synergistically enhance processes such as epithelial-to-mesenchymal transition (EMT) and matrix remodeling. This review explores the mechanistic interplay between obesity-induced inflammation and insulin resistance in cancer progression, discusses the molecular pathways involved, and highlights emerging therapeutic approaches targeting these intersecting tumor promotion axes.

1 September 2020 in Jornal de Pediatria (Versão em Português)
Verified
Journal Article
Open access
CJCíntia Junges
Cíntia Junges
TMTania Macahdo
Tania Macahdo
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
RRRudimar Riesgo
Rudimar Riesgo
EMElza Daniel de Mello
Elza Daniel de Mello

29 May 2026 in Clinical and Translational Science
Verified
Journal Article
Open access
BHBegoña de Las Heras
Begoña de Las Heras
COClaudine Oelke
Claudine Oelke
PAPamela Atwell
Pamela Atwell
HHHector Herrero
Hector Herrero
PFPaulo Ricardo Santos Nunes Filho
Paulo Ricardo Santos Nunes Filho
ECEmiliano Calvo
Emiliano Calvo
Radiolabeled mass balance human studies are a critical component of clinical pharmacology programs supporting the development of new investigational drugs. These studies provide information about absorption, metabolism, and excretion (AME) of the parent drug and metabolite(s) in the human body and are normally conducted in healthy volunteers (HVs). However, in some instances, based on the characteristics and toxicity of the molecule, conducting the study in HVs may not be a viable option and therefore cancer patients (CPs) need to be enrolled. Successful navigation of aspects such as pharmacologic characteristics, dose administration, patient clinical status and comorbidities, confinement period, study extension, team training, and requirements of the hospitals/units are essential to successfully deliver radiolabeled mass balance studies in CPs. This article provides an overview of the main aspects that must be taken into consideration to conduct AME studies in CPs.